| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vivo |
AU-15330 (10 and 30 mg/kg; intravenously; 5 days per week for 3 weeks) showed no significant toxicity in immunocompetent mice [1]. AU-15330 (60 mg/kg with or without enzalutamide 10 mg/kg; intravenously; 3 days per week; access; 5 days per week for 5 weeks) effectively inhibits tumor growth by more than 20% Causes disease regression in animals. The combination regimen induced the most potent AU-15330 (60 mg/kg with or without 10 mg/kg enzalutamide; iv; 3 days per week; side; 5 days per week for 5 weeks) as a single agent and It interacts well with enzalutamide and strongly inhibits the growth of C4-2B cell line-derived CRPC xenografts in intact mice [1]. AU-15330 (60 mg/kg with or without 10 mg/kg enzalutamide; iv; 3 days per week; sidewall 5 days per week for 5 weeks) significantly inhibits Tumor growth, resulting in tumor regression in more than 30% of animals, was induced in the CRPC variant model of MDA-PCa-146-12 PDX via a tumor-suffocating nozzle [1].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: VCaP castration-resistant tumor model (sixweeks old male CB17 severe combined immunodeficiency (SCID) mice) [1]
Doses: 60 mg/kg with or without 10 mg/kg enzalutamide Route of Administration: intravenous (iv) (iv)injection (3 days per week)); po (5 days per week for 5 weeks) Experimental Results: Inhibited tumor growth and induced disease regression in more than 20% of animals. Combination therapy induced the most potent antitumor effect and regression occurred in all animals. Animal/Disease Models: C4-2B non-castrated tumor model (sixweeks old male CB17 severe combined immunodeficiency (SCID) mice) [1] Doses: 60 mg/kg with or without 30 mg/kg enzalutamide Doses: IV (3 days per week); PO (5 days per week for 4 weeks) Experimental Results: As a single agent and synergistically with enzalutamide, strong inhibition of C4-2B cell line in intact mice Growth of derived CRPC xenografts. |
| References |
[1]. Xiao L, et al. Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. Nature. 2022;601(7893):434-439.
|
| Molecular Formula |
C39H49N9O5S
|
|---|---|
| Molecular Weight |
755.93
|
| CAS # |
2380274-50-8
|
| Related CAS # |
AU-16235;2380275-40-9
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
C(N1C[C@H](O)C[C@H]1C(=O)N[C@H](C1C=CC(C2SC=NC=2C)=CC=1)C)(=O)[C@H](C(C)(C)C)NC(=O)CN1CCN(C2=C(N=NC(C3C=CC=CC=3O)=C2)N)CC1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~140 mg/mL (~185.20 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.5 mg/mL (4.63 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 35.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3.5 mg/mL (4.63 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 35.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3.5 mg/mL (4.63 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3229 mL | 6.6144 mL | 13.2287 mL | |
| 5 mM | 0.2646 mL | 1.3229 mL | 2.6457 mL | |
| 10 mM | 0.1323 mL | 0.6614 mL | 1.3229 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
